Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: Communication from the SSC of the ISTH
Journal Title
Journal of Thrombosis and Haemostasis
Publication Type
Jul 18
Abstract
BACKGROUND: Given the role of platelets in coronary artery disease (CAD), assessment of a soluble platelet activation marker may be useful to improve thrombotic risk stratification. Therefore, we performed a meta-analysis investigating the association between levels of 14 such markers with CAD. METHODS: PubMed, Web of Science and EMBASE were searched until November 2024. The primary endpoint was the difference in levels of 11-dehydro-thromboxane B(2), 2,3-dinor-TXB(2), β-thromboglobulin, sCD40L, glycocalicin, GPV, GPVI, matrix metalloproteinase-9 (MMP-9) and 2 , Platelet Factor 4 (PF4), sP-selectin, SCUBE1, serotonin and thrombospondin 1(TSP-1) between CAD patients and healthy subjects (HS) in plasma and/or serum. When possible, CAD patients were stratified into acute coronary syndrome (ACS) and chronic coronary disease (CCD). Standardized mean difference (SMD) was calculated. RESULTS: Due to studies' heterogeneity, meta-analysis was performed for sCD40L, sGPV, MMP-9, PF4, sP-selectin, SCUBE1 and TSP-1. All markers but TSP-1 were significantly elevated in CAD patients versus HS. Differences in sCD40L and SCUBE1 were statistically significant only when plasma and serum studies were combined. When compared to HS the differences were bigger in ACS versus CCD for MMP-9 (SMD: 2.49 vs 0.49), PF4 (SMD: 2.01 vs 0.96), and sP-selectin (SMD: 1.81 vs 0.63). Publication bias was identified for sCD40L and in ACS for sP-selectin and PF4. CONCLUSIONS: The increased levels of sCD40L, sGPV, MMP-9, PF4, sP-selectin and SCUBE1 in CAD patients compared to HS provide a rationale for designing new studies to address the potential of such molecules as biomarkers for thrombotic risk stratification.
Publisher
Elsevier
Keywords
coronary artery disease; meta-analysis; platelet activation; soluble biomarker; thrombotic risk
Research Division(s)
Blood Cells and Blood Cancer
PubMed ID
40685139
Open Access at Publisher's Site
https://doi.org/10.1016/j.jtha.2025.07.014
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-07-28 03:09:54
Last Modified: 2025-07-28 03:11:13
An error has occurred. This application may no longer respond until reloaded. Reload 🗙